| 2024-11-19 | -5.62 % |
- Moderna (MRNA) stock declined by 5.62% due to broader market trends affecting healthcare stocks and investor sentiment following mixed earnings performance from related companies, such as Medtronic, which faced supplier issues despite reporting better-than-expected revenue.
- Moderna (MRNA) stock fell by -5.62% after Wolfe Research initiated coverage with an underperform rating and a $40 price target, amid a series of negative adjustments to price targets and ratings from other analysts.
- Moderna (MRNA) stock fell by 5.62% after Huntington National Bank reported reducing its holdings in the company by nearly a third, combined with negative sentiment from several analysts downgrading their ratings and lowering price targets for the stock.
- Moderna (MRNA) stock fell 5.62% following news of the termination of its collaboration with Metagenomi, which was revealed in a class action lawsuit alleging misleading statements by Metagenomi's management regarding the partnership's future.
- Moderna (MRNA) stock fell 5.62% due to concerns raised after President-elect Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as Health and Human Services secretary, which negatively impacted vaccine manufacturer stocks.
Additionally, finance departments are increasingly planning to use AI for greater efficiency, potentially leading to reduced workforce needs, while investors are adjusting their expectations following recent economic signals and election outcomes.
- Moderna (MRNA) stock fell by 5.62% due to concerns surrounding the nomination of Robert F. Kennedy Jr., a prominent anti-vaccine activist, to lead the Department of Health and Human Services under Trump's new administration.
- The article discusses a class action lawsuit against Metagenomi, Inc. following the termination of its collaboration with Moderna, which has likely contributed to a decline in Moderna’s stock price by 5.62%.
Moderna's stock decline is attributed to the negative market reaction to the termination of the collaboration agreement with Metagenomi, raising concerns over its business prospects.
- The article discusses the decline of Moderna (MRNA) stock by -5.62%, which may be attributed to concerns over the company’s future revenue prospects as it faces pressure from competitors and shifts in vaccine demand.
- The article discusses the decline of Moderna (MRNA) stock by 5.62%, attributing part of the decrease to the termination of its collaboration agreement with Metagenomi, which was a crucial aspect of Metagenomi's business model and likely raised concerns among investors about future prospects.
|
| 2024-11-18 | +7.22 % |
- Moderna (MRNA) stock increased by 7.22% last night, likely driven by positive investor sentiment following the recent results of the U.S. presidential election that may have boosted market confidence in pharmaceutical companies amid regulatory shifts.
Moderna's stock rise can be attributed to investor optimism regarding the potential impacts of the incoming Republican government, which is often perceived as more favorable to pharmaceutical and vaccine-related businesses, despite some initial concerns after Trump's controversial cabinet pick related to health policies.
- The article discusses a class action securities lawsuit against Metagenomi, Inc., which may have positively impacted Moderna (MRNA) stock by increasing investor interest in companies associated with biotechnology collaborations, leading to a 7.22% rise in its stock price.
- Moderna (MRNA) stocks were up 1.3% amidst overall market caution following the volatility after President Trump's election, influenced by investor sentiment regarding potential economic policies and the recent appointment of a vaccine skeptic to a health role, which has caused fluctuations in vaccine-related stocks.
The increase in Moderna's stock is likely reflective of investor optimism, despite the broader market uncertainties.
- Moderna (MRNA) stock increased by 7.22% following positive investor sentiment and potential announcements about its future products, leading to market optimism about its financial performance and growth prospects.
- The article discusses Donald Trump's plans for his second term, focusing on significant reductions in government agencies under the guidance of his appointed co-chair Vivek Ramaswamy, who proposes sweeping changes to the executive branch, potentially leading to mass budget cuts and the removal of certain government entities.
Modern (MRNA) stock likely rose by 7.22% last night due to market reactions to political developments and potential changes in government policies that could affect the biotech sector, along with investor optimism around the company's future prospects amidst Trump's administration's emphasis on efficiency and budget management.
- Moderna (MRNA) stock rose by 7.22% likely due to positive developments or investor sentiment surrounding its ongoing vaccine and therapeutic advancements, although specifics about the catalyst for this increase are not detailed in the article provided.
- Moderna's (MRNA) stock rose 7.22% as part of a broader recovery in U.S. stocks following a sharp decline, likely boosted by investors reassessing the potential economic impacts of Trump's presidential policies, despite previous concerns about his anti-vaccine stance.
- Moderna (MRNA) stock rose 7.2% on a day when most U.S. stocks showed a recovery from previous declines, as investors reacted to broader market dynamics influenced by political events and economic indicators, despite ongoing concerns about appointment of Robert F. Kennedy Jr. as head of the Department of Health and Human Services, a potential negative for vaccine manufacturers.
- Moderna's stock (MRNA) rose by 7.22% after experiencing a decline earlier in the week, primarily due to investor reactions to Donald Trump's announcement of Robert F. Kennedy Jr. leading Health and Human Services, which raised concerns about potential vaccine bans and could impact future vaccine market dynamics.
|
| 2024-11-15 | -7.34 % |
- Moderna (MRNA) stock fell by 7.34% after investors reacted negatively to Donald Trump's nomination of vaccine critic Robert F. Kennedy Jr., raising concerns about the potential impact on major pharmaceutical companies engaged in vaccine development.
- Moderna (MRNA) stock dropped 7.34% primarily due to the appointment of Robert F. Kennedy Jr., a noted vaccine skeptic, as the head of the Department of Health and Human Services by President-elect Donald Trump, which negatively impacted shares linked to vaccine developers.
- Moderna's (MRNA) stock fell 7.34% amid broader market declines, primarily due to concerns over potential profit impacts following President-elect Donald Trump's consideration of appointing anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Services, creating uncertainty for investors in the vaccine sector.
- Moderna's stock (MRNA) fell by 7.34% due to concerns triggered by Donald Trump appointing vaccine skeptic Robert F. Kennedy Jr. as head of the Department of Health and Human Services, leading investors to fear potential negative impacts on the pharmaceutical industry.
- Moderna's (MRNA) stock fell by 7.34% after worries arose from Donald Trump's nomination of Robert F. Kennedy Jr., a vaccine skeptic, to lead the Department of Health and Human Services, which negatively affected the shares of major pharmaceutical companies.
- Moderna (MRNA) stock fell 7.34% due to concerns about potential profit impacts following President-elect Trump's nomination of Robert F. Kennedy Jr., an antivaccine activist, to lead the Department of Health and Human Services, leading to broader declines in the vaccine and biotech sectors.
- Moderna (MRNA) stock fell 7.34% as part of a broader market decline influenced by Federal Reserve Chair Jerome Powell's hawkish stance on interest rates, combined with negative sentiment in the healthcare sector following President-elect Donald Trump's appointment of Robert F. Kennedy Jr. as head of Health and Human Services, raising concerns about future vaccine policy.
- Moderna (MRNA) stock dropped by 7.34% following Donald Trump's controversial appointment of vaccine opponent Robert F. Kennedy Jr. as the Secretary of Health and Human Services, which caused concern among investors about the potential negative impact on the pharmaceutical industry and public health policies.
|
| 2024-11-14 | -5.62 % |
|
| 2024-11-12 | +1.68 % |
|
| 2024-11-07 | -2.95 % |
|
| 2024-11-06 | -2.78 % |
|
| 2024-11-05 | -0.47 % |
|
| 2024-11-04 | -2 % |
|
| 2024-11-01 | +0.5 % |
|
| 2024-10-31 | -0.66 % |
- Moderna (MRNA) stock decreased by 0.66% due to broader market trends and possibly negative investor sentiment, although the article primarily discusses Microsoft and does not provide specific reasons for Moderna's decline.
- The article discusses the recent turmoil at 23andMe following the abrupt resignation of its board members and the appointment of new finance-focused directors, while also noting a decline in Moderna (MRNA) stock by 0.66%. Moderna's stock may have fallen due to ongoing market fluctuations and broader concerns in the biotech sector, which affects investor confidence in the company's future performance.
- Moderna (MRNA) stock declined by 0.66% due to a combination of institutional investors reducing their stakes, analysts lowering price targets and ratings, and insider selling activity, indicating potential waning confidence in the company's future performance.
- The article discusses a decline in Moderna (MRNA) stock, which fell by 0.66%, primarily due to the termination of its collaboration agreement with Metagenomi, a critical aspect of their partnership that raised concerns about the future of both companies.
- Moderna (MRNA) stock declined by 0.66% amid concerns related to its collaboration with Metagenomi, Inc., which was terminated earlier this year, leading to investor lawsuits and uncertainty about future earnings.
|
| 2024-10-30 | -0.91 % |
|
| 2024-10-29 | +0.77 % |
|
| 2024-10-28 | +3.22 % |
|
| 2024-10-24 | -1.11 % |
|
| 2024-10-23 | -0.02 % |
|
| 2024-10-22 | -0.74 % |
|
| 2024-10-21 | -0.55 % |
|
| 2024-10-18 | -1.31 % |
- Moderna (MRNA) stock declined by 1.31% amid a generally positive market performance with key indices setting new records and strong earnings reports from companies like Netflix overshadowing its performance, possibly reflecting investor concerns about the broader market dynamics and sentiment rather than specific issues with Moderna.
- Moderna (MRNA) stock recently declined by 1.31%, likely due to increased competition and market shifts affecting investor sentiment following its significant gains during the pandemic.
- Moderna (MRNA) stock declined by 1.31% following news of a terminated collaboration with Metagenomi, which was initially touted as a significant partnership during Metagenomi's IPO.
- Moderna's stock (MRNA) declined by 1.31% despite Vontobel Holding Ltd. significantly increasing its stake in the company by 148.2% in the third quarter, indicating a potential disconnect between institutional investment and market performance.
The drop in Moderna's stock may be attributed to broader market trends, company-specific news, or investor sentiment rather than the increase in institutional holdings.
- Moderna (MRNA) stock fell by 1.31% due to concerns arising from a class action lawsuit related to a collaboration with Metagenomi, Inc., which allegedly misled investors about the future of their partnership.
- Moderna (MRNA) stock fell by 1.31% due to increased activity in put options, suggesting bearish sentiment among investors, highlighting concerns about the company's financial performance despite a recent positive earnings report that beat estimates but showed significant revenue decline.
- Moderna (MRNA) stock fell by 1.31% following news that SeaCrest Wealth Management LLC reduced its stake in the company by 9.6%, amidst mixed analyst ratings and target price adjustments reflecting cautious sentiment regarding the company's future performance.
The decline in Moderna's stock can be attributed to several factors, including SeaCrest's reduction of their position, analyst downgrades and lowered price targets from various financial institutions, as well as the company's ongoing struggles with revenue and profitability.
- Moderna (MRNA) stock fell by 1.31% following a downgrade of its Q3 2024 earnings per share estimates by Zacks Research, which revised the expected loss from ($1.83) to ($1.88) per share, contributing to a negative sentiment around the company's financial outlook.
|
| 2024-10-17 | -4.59 % |
|
| 2024-10-16 | +0.26 % |
- The article discusses the legal notice issued by The Gross Law Firm regarding a class action lawsuit for shareholders of Metagenomi, Inc., related to the termination of its collaboration with Moderna, which affected Metagenomi's stock price but also coincided with a slight increase in Moderna (MRNA) stock by 0.26%.
Moderna's stock may have gone up due to market reactions to potential developments or positive sentiment around their ongoing projects, despite the setback faced by Metagenomi following the termination of its collaboration with Moderna.
- Moderna (MRNA) stock rose by 0.26% amid various analyst ratings, including a hold rating from Jefferies and upgrades from HSBC and Deutsche Bank, reflecting a mixed but generally stable outlook for the company despite price target reductions.
Moderna's stock increase may result from positive earnings that surpassed analyst expectations and ongoing interest from institutional investors, indicating a level of confidence in the company's future prospects.
- The article reports that Moderna's stock (MRNA) saw a slight increase of 0.26%, following news about a class action lawsuit involving Metagenomi Inc., which allegedly misled investors regarding its collaboration with Moderna. This rise in Moderna's stock may be attributed to investor sentiment regarding the potential implications of Metagenomi's legal troubles, reflecting a perception of stability or confidence in Moderna amidst the scrutiny faced by its former partner.
- Moderna (MRNA) stock rose by 0.26% in the wake of Novavax's setback with its vaccine development, suggesting that investors may view Moderna more favorably as an established player in the mRNA vaccine space amidst declining competition.
- The article discusses an investigation into Metagenomi, Inc. by the law firm Faruqi & Faruqi LLP due to potential legal claims related to false statements about its collaboration with Moderna, following the termination of their agreement, which led to Metagenomi's stock price decline.
Moderna (MRNA) stock might be up due to market reactions to broader industry dynamics or investor sentiment possibly benefiting from the ongoing developments in the biotech sector, despite specific issues surrounding Metagenomi.
|
| 2024-10-15 | -0.73 % |
|
| 2024-10-14 | -0.96 % |
|
| 2024-10-11 | +2.57 % |
- The article discusses a class action lawsuit targeting Metagenomi, Inc. and highlights the financial implications for investors following the termination of its collaboration agreement with Moderna, which could contribute to Moderna's stock price increase by signaling stability and independence from potential negative impacts associated with the lawsuit.
Moderna's stock may have gone up due to investor confidence stemming from the clarified separation from Metagenomi after the lawsuit, suggesting that the market views Moderna as less exposed to incoming legal challenges related to the IPO of Metagenomi.
- The article discusses a potential securities class action against Metagenomi following the termination of its collaboration with Moderna, while Moderna's stock (MRNA) rose by 2.57% potentially due to investor confidence in the company's ongoing business amidst challenges faced by its partner.
- Moderna (MRNA) stock rose 2.57% last night, largely due to increased institutional investment, including a 7.3% stake increase by Truist Financial Corp, which signals growing confidence in the company's potential despite recent financial challenges.
- The article discusses class action lawsuits filed on behalf of shareholders of various companies, including Metagenomi, which disclosed that a collaboration with Moderna would end sooner than expected, potentially affecting investor sentiment. Moderna's (MRNA) stock increased by 2.57% possibly due to investor optimism surrounding its ongoing developments or reassessment of its market position despite the lawsuit news.
- The article primarily discusses class action lawsuits involving various companies, but it highlights that Moderna's (MRNA) stock rose by 2.57% due to speculation regarding its collaboration with Metagenomi, which is mentioned in legal filings. The increase in Moderna's stock is likely related to investor confidence stemming from ongoing developments in its collaborations and potential business prospects.
|
| 2024-10-10 | -3.45 % |
|
| 2024-10-09 | +0.8 % |
|
| 2024-10-08 | -0.56 % |
- Moderna (MRNA) stock declined by 0.56% following CFO James M. Mock's sale of 715 shares, which may have raised concerns among investors about insider selling.
- The article discusses a podcast interview with Vince Aita of Cutter Capital, who shares his journey from academia to finance and offers insights on biotech investing, but notes that Moderna (MRNA) stock recently experienced a decline of 0.56%.
The drop in Moderna (MRNA) stock could be attributed to various factors, including market reactions to biotech sector trends, investor sentiment, or company-specific news that may have raised concerns about its future performance or financial stability.
- The Moderna (MRNA) stock declined by 0.56% due to allegations of misleading statements regarding the effectiveness of its respiratory syncytial virus vaccine, mRNA-1345, which overstated its clinical and commercial prospects.
- Moderna (MRNA) stock fell by 0.56% amid allegations that Metagenomi Inc. misled investors about its collaboration with Moderna, which was terminated shortly after Metagenomi's IPO, leading to a decline in confidence regarding both companies.
- Moderna (MRNA) stock fell by 0.56% due to concerns over a terminated collaboration agreement with Metagenomi, which impacted investor confidence in both companies' future prospects.
|
| 2024-10-07 | -2.46 % |
|
| 2024-10-04 | -1.42 % |
- The article discusses a class action lawsuit involving Metagenomi, Inc., which is linked to Moderna due to their previous collaboration that was terminated, likely contributing to a decline in Moderna's stock price by 1.42%. The stock decline may be attributed to investor concerns regarding the fallout from the termination of the collaboration between Metagenomi and Moderna, which could negatively impact investor perceptions of Moderna's future prospects.
- Moderna's stock (MRNA) fell by 1.42% after Dana Investment Advisors Inc. significantly reduced its stake in the company by 75.6% in the second quarter.
- Moderna (MRNA) stock fell by 1.42% amid heightened competition in the weight-loss drug market, with emerging players like Viking Therapeutics stirring investor focus away from established giants including Pfizer, who are struggling to keep pace with quicker-moving rivals in this rapidly expanding sector.
- Moderna (MRNA) stock declined by 1.42% likely due to market reactions to updates and competition among COVID-19 vaccines, as well as concerns regarding vaccine efficacy and public interest in vaccinations.
- Moderna (MRNA) stock declined by 1.42% largely due to market reactions following the termination of its collaboration with Metagenomi, which was disclosed shortly after Metagenomi's IPO, leading to concerns about the financial prospects of both companies.
- Moderna (MRNA) stock experienced a decline of 1.42% due to concerns stemming from a class action lawsuit against Metagenomi, which revealed that their collaboration with Moderna would be ceasing, leading to doubts about the company's future business prospects.
|
| 2024-10-03 | -3.31 % |
|
| 2024-10-02 | -1.2 % |
|
| 2024-10-01 | -4.34 % |
|
| 2024-09-30 | +1.64 % |
|
| 2024-09-27 | +2.85 % |
- Moderna (MRNA) stock rose by 2.85% amid ongoing legal issues related to Metagenomi Inc., including allegations that Metagenomi misled investors about its collaboration with Moderna which was recently terminated, potentially stabilizing investor sentiment in the biotech sector.
- The article discusses a class action lawsuit filed against Metagenomi Inc., alleging issues with its collaboration with Moderna, which negatively impacted Metagenomi's stock, while also noting that Moderna (MRNA) stock rose by 2.85% likely due to investor confidence bolstered by its ongoing role in developing genetic therapies, despite Metagenomi's challenges.
- The article discusses a class action lawsuit against Metagenomi, Inc. regarding its initial public offering and its collaboration with Moderna, which may indirectly impact Moderna's stock price positively by clarifying its business relationships and reducing investor uncertainty.
Modern's stock (MRNA) likely went up by 2.85% due to positive investor sentiment or market reactions to their ongoing business developments, possibly linked to the highlighted partnership or litigation news surrounding Metagenomi.
- The article discusses a securities class action lawsuit filed against Metagenomi, Inc. surrounding misrepresentations about its collaboration with Moderna, which might have contributed to a rise in Moderna's stock by 2.85% due to investor optimism or confidence stemming from the legal developments associated with its partnership.
|
| 2024-09-26 | +0.46 % |
|
| 2024-09-25 | -0.47 % |
|
| 2024-09-24 | -0.31 % |
|
| 2024-09-23 | -2.36 % |
|
| 2024-09-20 | -3.43 % |
|
| 2024-09-19 | -2.63 % |
|
| 2024-09-18 | -2.96 % |
|
| 2024-09-17 | +4.08 % |
|
| 2024-09-16 | +1.3 % |
- Moderna (MRNA) stock rose by 1.3% due to positive investor sentiment linked to the Federal Reserve's anticipated rate cuts and the overall market outlook, which suggests favorable conditions for investments in technology and healthcare sectors, including biotech.
- Moderna (MRNA) stock experienced a 1.3% increase, likely influenced by investor optimism surrounding the general positive momentum in the biotechnology sector, particularly following JPMorgan's upgrade of BioNTech (BNTX) amid encouraging data from its oncology pipeline, which parallels themes of diversification and growth that also apply to Moderna.
- Moderna (MRNA) stock increased by 1.3% due to rising COVID-19 levels and the approach of flu season, which is driving demand for updated respiratory virus vaccines, including those provided by Moderna.
- Moderna (MRNA) stock rose by 1.3% amid rising Covid-19 levels in the United States and an approaching respiratory disease season, as the demand for updated Covid-19 vaccines from Moderna and Pfizer increases to help combat the circulating variants.
The stock's increase is likely due to the anticipation of higher vaccine uptake as public health officials stress the importance of vaccination to mitigate the impact of upcoming respiratory illnesses, including Covid-19, flu, and RSV.
|
| 2024-09-13 | -2.01 % |
|
| 2024-09-12 | -12.36 % |
|
| 2024-09-11 | +0.29 % |
|
| 2024-09-10 | +3.49 % |
|
| 2024-09-09 | +5.1 % |
|
| 2024-09-06 | -0.75 % |
|
| 2024-09-05 | +1.31 % |
- Moderna (MRNA) stock rose by 1.31% following news of a class action lawsuit against the company regarding allegations that it misled investors about the efficacy of its RSV vaccine, mRNA-1345, which may indicate optimism about its future or resolution of related uncertainties.
The stock increase might be attributed to investor sentiment reacting positively to the developments or recent performance indicators, despite the underlying legal issues.
- Moderna (MRNA) stock rose 1.31% due to the FDA's approval of updated vaccines amid a surge in COVID-19 infections, coinciding with the end of the federal Bridge Access program, which will require millions of uninsured Americans to pay out-of-pocket for vaccines.
- Moderna's (MRNA) stock rose 1.31% after early testing showed that its mRNA mpox vaccine surpasses licensed competitors in alleviating symptoms and potentially reducing transmission, indicating its potential to expand beyond the Covid-19 market. Additionally, Nichole Wischoff has successfully raised $50 million for Wischoff Ventures to invest in over 30 startups, primarily in fintech, logistics, and manufacturing.
|
| 2024-09-04 | -0.62 % |
- Moderna (MRNA) stock fell by 0.62% amidst increased competition from Novavax's newly authorized COVID vaccine, which adds options for consumers alongside Moderna's own updated mRNA vaccines, reflecting the ongoing adaptation of the market in response to evolving COVID treatment strategies.
- Moderna (MRNA) stock recently declined by 0.62%, partially due to the Chief Legal Officer's stock sale related to tax obligations and ongoing concerns about the company's significant revenue decline, executive transactions, and cautious analyst outlooks on future sales and profitability.
- Moderna (MRNA) stock declined by 0.62% due to ongoing class action lawsuits alleging that the company made materially false and misleading statements about the effectiveness and commercial prospects of its mRNA-1345 product.
- Moderna's (MRNA) stock fell by 0.62% primarily due to concerns about low demand for COVID-19 vaccines, as pediatricians across the U.S. are scaling back orders in anticipation of parents' waning interest following a recent trend of underwhelming vaccination rates among eligible children.
- Moderna (MRNA) stock fell by 0.62% due to concerns over the company's financial performance and ongoing losses, suggesting a need for operational improvements to stabilize its profitability.
- Moderna (MRNA) stock has declined by 0.62% following the FDA's authorization of a new COVID-19 vaccine from Novavax, providing an alternative to its and Pfizer's vaccines, which may lead to reduced demand for Moderna's products.
- Moderna (MRNA) stock declined by 0.62% likely due to market reactions to developments in the COVID-19 vaccine landscape, including updated vaccine approvals and increased competition from other companies like Pfizer and Sunshine Biopharma, which are also advancing their COVID-19 treatments.
|
| 2024-09-03 | -5.76 % |
|
| 2024-08-30 | -0.24 % |
|
| 2024-08-14 | -0.78 % |
|
| 2024-08-12 | -4.29 % |
|
| 2024-08-08 | +3.4 % |
- Moderna (MRNA) stock rose by 3.4% due to positive developments in its collaborative research partnerships, particularly the progress and promising data from clinical trials related to its PROBODY therapeutic platform with CytomX Therapeutics.
- The article discusses the recent 3.4% increase in Moderna (MRNA) stock, attributing this rise to a positive outlook sparked by Needham's upgrade of Personalis, Inc. (PSNL), as well as Personalis' strong second-quarter results and upward revenue guidance, which bolster overall investor sentiment within the biotechnology sector.
- Moderna (MRNA) stock rose 3.4% likely due to positive developments at Personalis Inc., including a significant revenue increase and raised full-year guidance, which reflects investor confidence in strategic partnerships, including those with Moderna.
- Moderna (MRNA) stock increased by 3.4% likely due to positive developments and collaborations in the personalized cancer vaccine sector, particularly its partnership with Personalis, which has shown strong growth and promising advancements in its technology and services.
|
| 2024-08-06 | -1.73 % |
|
| 2024-08-05 | -3.27 % |
|
| 2024-08-02 | -8.06 % |
- The article discusses the advancements in the biotechnology market, specifically highlighting Moderna's ongoing development of mRNA vaccines funded by federal resources, amidst an overall decline in biotechnology venture capital funding and mixed investment opportunities.
Moderna's (MRNA) stock may have gone down by 8.06% due to a broader decline in biotech funding and market challenges, as reported by the EY Biotechnology Report 2024 which indicates that only companies with strong clinical data or market-ready assets are attracting significant investments, leading to investor caution.
- Moderna (MRNA) stock fell sharply by 8.06% amid a broader market decline triggered by disappointing job growth data, which heightened recession fears and led to increased volatility across major indexes.
The decline in Moderna's stock was part of a larger market selloff following a report that indicated the U.S. economy added fewer jobs than expected, raising concerns about a potential recession.
- Moderna (MRNA) stock fell 8.06% following the significant insider sale by director Noubar Afeyan, which may signal a lack of confidence amid the company's recent financial losses, declining vaccine sales, and lowered sales forecasts, despite some positive developments in other areas.
|
| 2024-08-01 | -21.01 % |
- Moderna (MRNA) stock experienced a significant decline of 21% due to disappointing disclosures about setbacks in its post-pandemic portfolio, which left investors questioning the company's future prospects as broader market concerns about a slowing economy intensified.
- Moderna (MRNA) stock fell 21% due to the company lowering its full-year sales forecast amidst disappointing international revenue expectations, despite reporting better-than-expected quarterly results.
- Moderna (MRNA) stock fell by 21.01% due to a significant 30% decline in Q2 sales, resulting in the company dropping below its 200-day moving average.
- Moderna (MRNA) stock fell by 21.01% due to concerns about the company's declining revenue and future growth prospects, particularly following difficulties in vaccine sales and market competition.
- Moderna (MRNA) stock fell by 21.01% amid a turbulent earnings season and macroeconomic uncertainties, including disappointing factory data and mixed signals from other major companies, as investors reacted negatively to the company's latest earnings report.
- Moderna (MRNA) stock fell by 21.2% after the company revised its full-year sales outlook down to $3 billion to $3.5 billion, citing low European Union sales, deferred international revenue, and increased competition in the respiratory vaccine market, despite beating second-quarter sales expectations.
- Moderna (MRNA) stock fell by 21.01% following Jefferies' revision of its price target from $180 to $120 and concerns over a projected $500 million to $1 billion reduction in 2024 revenue due to lower pricing of COVID-19 vaccines, deferrals in advanced purchase agreements, and modest expectations for its RSV vaccine.
- Moderna's stock fell by over 21% following the company's disappointing disclosures about setbacks in its COVID vaccine market in Europe, challenges in the competitive landscape for its new RSV vaccine, and a cut in its sales expectations for the year.
The primary reasons for the decline in Moderna's stock include its struggles to penetrate the COVID vaccine market in Europe, disappointing sales from its RSV vaccine launch due to stiff competition, a significant reduction in its projected sales outlook for 2024, and ongoing net losses that raise doubts about its profitability.
- Moderna (MRNA) stock fell by 18% due to a reduction in its full-year revenue guidance attributed to low sales in Europe and increased competition in the U.S. vaccine market.
|
| 2024-07-31 | +0.32 % |
|
| 2024-07-25 | +1.87 % |
|
| 2024-07-24 | -2.52 % |
|
| 2024-07-16 | +3.01 % |
|
| 2024-07-12 | -1.11 % |
|
| 2024-07-09 | -0.33 % |
|
| 2024-07-08 | -1.58 % |
|
| 2024-06-28 | -2.01 % |
|
| 2024-06-26 | -11.01 % |
|
| 2024-06-24 | +2.7 % |
|
| 2024-06-20 | +0.85 % |
|
| 2024-06-10 | -1.6 % |
- The article discusses Moderna Inc. preparing for the post-Covid era and mentions that last night Moderna (MRNA) stock was down by 1.6%, possibly due to factors such as market fluctuations, economic conditions, or profit-taking by investors.
- Summary: Moderna's combination vaccine for COVID-19 and influenza showed a stronger immune response in adults aged 50 and over, as per a late-stage trial, with plans for a potential launch in 2025 or 2026.
Reason for Moderna (MRNA) stock decline: The stock might have gone down due to factors like overall market conditions, profit-taking by investors, or reactions to the latest results or announcements from the company regarding the trial of the combination vaccine.
- Moderna's stock went down by 1.6% last night despite the company announcing that its Covid/flu vaccine outperformed competitors like GSK and Sanofi, as well as its own Spikevax shot.
- Summary: Moderna's stock, represented by the ticker symbol MRNA, was down by 1.6% last night as the company, led by CEO Stéphane Bancel, prepares for the post-Covid era, aiming to restore confidence in the vaccines sector.
Reason for stock decline: The decline in Moderna's stock may be attributed to various factors such as overall market conditions, investor sentiment, news related to the company's vaccine development progress, or general economic outlook.
- The article highlights five companies with high profitability and low debt, including Graco Inc., A.O. Smith Corp., Mueller Industries Inc., Warrior Met Coal Inc., and Axcelis Technologies Inc., offering investment suggestions. Moderna Inc. (MRNA) stock went down by -1.6% likely due to various market factors affecting the biotechnology sector, such as regulatory news, vaccine distribution concerns, or general market volatility.
|
| 2024-06-05 | +6.54 % |
|
| 2024-05-31 | -5.9 % |
|
| 2024-05-29 | -3.45 % |
|
| 2024-05-21 | +1.9 % |
|
| 2024-05-20 | +6.1 % |
|
